ACMT urges clinical oversight for concentrated 7-OH products

Why it matters

The medical toxicology group’s statement gives clinicians and policymakers a current, specialty-society view of concentrated 7-OH products. It distinguishes those products from traditional leaf preparations while calling for more research.

The big picture

7-OH is present in trace amounts in kratom leaf and can also result from mitragynine metabolism. ACMT says concentrated 7-OH products became broadly available in U.S. retail and online markets in the late 2010s, and evidence on human safety, dosing, and pharmacokinetics remains incomplete.

Key findings

• ACMT says animal studies show 7-OH and related compounds can produce opioid-like effects.
• The statement cites clinical reports of intoxication, respiratory depression, dependence, withdrawal, overdose, and death associated with 7-OH.
• It reports that naloxone reversed 7-OH-associated respiratory depression in animal work and human case reports.
• The group says buprenorphine has been used to treat kratom- and 7-OH-related withdrawal.
• ACMT says there are no proven therapeutic benefits for 7-OH and no safe dose can be recommended.

What they say

“Additional clinical research is needed to better define their pharmacology, safety profile, and potential therapeutic applications.”

Bottom line

ACMT recommends that use of 7-OH occur only in appropriately overseen clinical research while its safety and therapeutic profile are clarified.